Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Edith Brutcher"'
Autor:
Lauren M. Postlewait, Volkan Adsay, Bassel F. El-Rayes, Cecilia G. Ethun, Zhengjia Chen, Charles A. Staley, Edith Brutcher, Juan M. Sarmiento, Shishir K. Maithel, David A. Kooby
Publikováno v:
Journal of Surgical Oncology. 114:336-341
Background Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO-001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P
Autor:
Lauren M, Postlewait, Cecilia G, Ethun, David A, Kooby, Juan M, Sarmiento, Zhengjia, Chen, Charles A, Staley, Edith, Brutcher, Volkan, Adsay, Bassel, El-Rayes, Shishir K, Maithel
Publikováno v:
Journal of surgical oncology. 114(3)
Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO-001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P 0.001; OS:22.8 vs. 20.2 mo; P = 0.01)]. Addition of cisplatin (Cis) to Gem has resulted in increased PFS for advanc
Autor:
Charles A. Staley, Lauren M. Postlewait, Volkan Adsay, Bassel F. El-Rayes, Edith Brutcher, Cecilia G. Ethun, Shishir K. Maithel, Juan M. Sarmiento, David A. Kooby
Publikováno v:
Journal of Clinical Oncology. 34:230-230
230 Background: Standard adjuvant treatment for resected pancreatic adenocarcinoma is gemcitabine (Gem) (CONKO-001 trial: Gem vs placebo DFS 13.4 vs 6.7 mo; p2) / Cis (50 mg/m2) Day 1/8/15, Q28d for 6 cycles. After enrolling 5 pts, this was modified